Triclabendazole (commercial names: veterinary, liquid: Fasinex ; human, tablets: Egaten , both manufactured by Novartis) is a member of the benzimidazole family of anthelmintics. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but no carbamate group. Benzimidazoles such as triclabendazole are generally accepted to bind to beta-tubulin and prevent the polymerization of the microtubules of which they are part.

Starting at
| Systematic (IUPAC) name | |
|---|---|
| 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category | ? |
| Legal status |
? |
| Routes of administration | ? |
| Pharmacokinetic data | |
| Metabolism | oxidation to the sulfone and sulfoxide parent compound |
| Biological half-life | 22 – 24 hs |
| Excretion | >95% in faeces, 2% in urine, and < 1% in milk |
| Identifiers | |
|---|---|
| CAS Number | 68786-66-3 |
| ATC code | P02BX04 QP52AC01 |
| PubChem | CID: 50248 |
| ChemSpider | 45565 |
| UNII | 4784C8E03O |
| ChEMBL | CHEMBL1086440 |
| Chemical data | |
|---|---|
| Formula | C14H9Cl3N2OS |
| Molecular mass | 359.658 |
|
SMILES[show] |
|
|
InChI[show] |
|